NF2 clinical trials and studies http://www.advocurenf2.org/02_nf2clinicaltrials.html http://blogs.law.harvard.edu/tech/rss Sun, 4 Jul 2010 13:00:00 -0400 Harvard Medical School / Massachusetts Eye and Ear Infirmary Boston MA. Adrian Priesol, M.D. at (617) 573-4148. email: adrian_priesol@meei.harvard.edu . The general clinical goal for our study is to quantify motion perception for a range of vestibular disorders. A long-term goal is to develop new clinical tests to provide early diagnosis for vestibular disorders. These clinical research efforts are part of a broader basic science investigation of vestibular thresholds. At this time, we are seeking NF2 patients who have complete loss of vestibular (i.e., “balance/equilibrium organ”) function in both ears following surgical removal of tumors from both ears. Travel reimbursement would be paid for all qualifying volunteers. http://www.masseyeandear.org/research/clinical-trials/otolaryngology-clinical-trials/wanted-vrstudy-participants/ Sun, 4 Jul 2010 13:00:00 -0400 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas, ClinicalTrials.gov Identifier: NCT01125046. http://www.clinicaltrials.gov/ct2/show/NCT01125046?term=nf2&rank=11 11 Jun 2010 23:00:00 -0400 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors, ClinicalTrials.gov Identifier: NCT00973739. http://www.clinicaltrials.gov/ct2/show/NCT00973739?term=nf2&rank=1 3 Sep 2009 12:00:00 -0500 Concentration and Activity of Lapatinib in Vestibular Schwannomas, ClinicalTrials.gov Identifier: NCT00863122. http://clinicaltrials.gov/ct2/show/NCT00863122?term=nf2&rank=3 13 Mar 2009 12:00:00 -0500 PTC299 for Treatment of Neurofibromatosis Type 2, ClinicalTrials.gov Identifier: NCT00911248. http://clinicaltrials.gov/ct2/show/NCT00911248?term=nf2&rank=1 28 May 2009 12:00:00 -0500 Natural History Study of Patients With Neurofibromatosis Type 2, ClinicalTrials.gov Identifier: NCT00598351. http://clinicaltrials.gov/ct2/show/NCT00598351?term=NF2&rank=2 10 Jan 2008 12:00:00 -0500 Neurofibromatosis Type 2 Associated Color Vision Anomalies and Birth Defects: Incidence and Insights, http://www.ctf.org/images/for-scientists/nf2%20flyer-revised.pdf Fri, 26 Feb 2010 12:00:00 -0500 Sunitinib in Treating Patients With Recurrent or Unresectable Meningioma, Intracranial Hemangiopericytoma, or Intracranial Hemangioblastoma, ClinicalTrials.gov Identifier: NCT00561665. http://clinicaltrials.gov/ct2/show/NCT00561665?term=nf2&rank=10 20 Nov 2007 12:00:00 -0500 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma, ClinicalTrials.gov Identifier: NCT00589784. http://clinicaltrials.gov/ct2/show/NCT00589784?term=nf2&rank=11 26 Dec 2007 12:00:00 -0500 Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity, ClinicalTrials.gov Identifier: NCT01024946. http://clinicaltrials.gov/ct2/show/NCT01024946?term=nf2&rank=8 2 Dec 2009 12:00:00 -0500 Monthly SOM230C for Recurrent or Progressive Meningioma, ClinicalTrials.gov Identifier: NCT00859040 http://clinicaltrials.gov/ct2/show/NCT00859040?intr=Pasireotide&rank=9 9 Mar 2009 12:00:00 -0500 Phase II Study of SOM230 in Patients with Recurrent or Progressive Meningioma, ClinicalTrials.gov Identifier: NCT00813592 http://clinicaltrials.gov/ct2/show/NCT00813592?term=NCT00813592&rank=1 17 Nov 2009 12:00:00 -0500